Literature DB >> 12955186

A canine study of immunotherapy in scorpion envenomation.

Fekri Abroug1,2, Semir Nouira3,4, Souheil El Atrous4, Lamia Besbes3,4, Riadh Boukef3,4, Mohamed Boussarsar3,4, Soudani Marghli3,4, Joëlle Eurin5, Christiane Barthelemy5, Mohamed El Ayeb6, Koussay Dellagi6, Alain Carayon5.   

Abstract

OBJECTIVE: To evaluate the effects of scorpion venom and antivenom in experimental envenomation.
DESIGN: Prospective, controlled animal study.
SETTING: University research laboratory
SUBJECTS: Twenty-nine anesthetized and ventilated dogs.
INTERVENTIONS: The first group of animals had venom alone (0.05 mg/kg). Animals from the second group had simultaneous administration of 10 ml of scorpion antivenom (SAV). In the third and fourth groups, 10 ml and 40 ml SAV, respectively, were injected 10 min following venom. MEASUREMENTS AND
RESULTS: Hemodynamic parameters using right heart catheter were recorded and dosage of catecholamines, neuropeptide Y (NPY), endothelin-1, and atrial natriuretic peptide (ANP) were performed at baseline and during 60 min following envenomation. In the control group, at 5 min, there was a sharp increase in pulmonary artery occluded pressure (PAOP, from 2 mmHg to 23 mmHg), mean arterial pressure (MAP, from 125 mmHg to 212 mmHg) and systemic vascular resistance (SVR, from 2450 dyn sec(-1 )m(5) to 5775 dyn sec(-1 )m(5), P<0.05 for all). Heart rate, cardiac output, and stroke volume decreased. There was a 40-fold increase in epinephrine and norepinephrine plasma concentrations. Circulating NPY and ANP dosages increased too. PAOP and MAP decreased thereafter to reach baseline levels. Simultaneous administration of SAV with venom totally offset the hallmarks of scorpion envenomation. Delayed administration of SAV at any dosage failed to alter the features of scorpion envenomation.
CONCLUSION: While simultaneous administration of SAV and scorpion venom is effective in preventing scorpion envenomation-related manifestations, delayed administration of SAV, either at standard or elevated dosages, failed to alter any of the scorpion envenomation features.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12955186     DOI: 10.1007/s00134-003-1947-0

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  1 in total

1.  Treatment of cardiovascular manifestations of human scorpion envenoming: is serotherapy essential?

Authors:  H S Bawaskar; P H Bawaskar
Journal:  J Trop Med Hyg       Date:  1991-06
  1 in total
  5 in total

Review 1.  Year in review in intensive care medicine-2003. Part 3: intensive care unit organization, scoring, quality of life, ethics, neonatal and pediatrics, and experimental.

Authors:  Edward Abraham; Peter Andrews; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Geoffrey Dobb; Jean-Yves Fagon; Johan Groeneveld; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Michael Pinsky; Peter Radermacher; Marco Ranieri; Christian Richard; Robert Tasker; Benoit Vallet
Journal:  Intensive Care Med       Date:  2004-06-26       Impact factor: 17.440

2.  Scorpion envenomation: from a neglected to a helpful disease?

Authors:  Fekri Abroug; Lamia Ouanes-Besbes; Slah Bouchoucha
Journal:  Intensive Care Med       Date:  2018-05-30       Impact factor: 17.440

3.  Direct vs. mediated effects of scorpion venom: an experimental study of the effects of a second challenge with scorpion venom.

Authors:  Lamia Ouanes-Besbes; Souhail El Atrous; Semir Nouira; Nicolas Aubrey; Alain Carayon; Mohamed El Ayeb; Fekri Abroug
Journal:  Intensive Care Med       Date:  2005-01-28       Impact factor: 17.440

4.  Anaphylaxis to scorpion antivenin and its management following envenomation by Indian red scorpion, Mesobuthus tamulus.

Authors:  Rahul Ramesh Bhoite; Girija Ramesh Bhoite; Dayanand N Bagdure; Himmatrao S Bawaskar
Journal:  Indian J Crit Care Med       Date:  2015-09

5.  Involvement of the Endothelin Receptor Type A in the Cardiovascular Inflammatory Response Following Scorpion Envenomation.

Authors:  Amina Sifi; Sonia Adi-Bessalem; Fatima Laraba-Djebari
Journal:  Toxins (Basel)       Date:  2020-06-12       Impact factor: 4.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.